The FDA has granted a Priority Review designation to the supplemental New Drug Application for the oral multikinase inhibitor Nexavar tablets, which are under evaluation for the treatment of locally advanced or metastatic radioactive iodine -refractory differentiated thyroid cancer.
http://www.pharmscope.com/news/DailyDetail.cfm?chosen=67735
http://www.pharmscope.com/news/DailyDetail.cfm?chosen=67735
No comments:
Post a Comment